Athira Pharma (NASDAQ:ATHA – Get Free Report) and OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
Valuation and Earnings
This table compares Athira Pharma and OnKure Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Athira Pharma | N/A | N/A | -$96.94 million | ($9.68) | -0.85 |
| OnKure Therapeutics | N/A | N/A | -$59.52 million | ($4.33) | -0.97 |
Institutional & Insider Ownership
57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Athira Pharma and OnKure Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Athira Pharma | N/A | -107.06% | -89.89% |
| OnKure Therapeutics | N/A | -61.02% | -55.99% |
Analyst Ratings
This is a summary of current recommendations and price targets for Athira Pharma and OnKure Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Athira Pharma | 1 | 0 | 0 | 0 | 1.00 |
| OnKure Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Athira Pharma presently has a consensus target price of $4.00, suggesting a potential downside of 51.34%. OnKure Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 539.81%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Athira Pharma.
Risk and Volatility
Athira Pharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Summary
OnKure Therapeutics beats Athira Pharma on 8 of the 11 factors compared between the two stocks.
About Athira Pharma
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
